GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (ASSIST_FL)
A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma
Sponsor: Novartis Pharmaceuticals
Listed as NCT01419665, this PHASE3 trial focuses on Follicular Lymphoma and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- Sandoz
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Ahmedabad, India , Alor Star, Malaysia , Ampang, Malaysia , Amritsar, India , Amsterdam, Netherlands , Aomori, Japan , Arkhangelsk, Russia , Ashkelon, Israel , Athens, Greece and 141 more locations